Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
27 hedge funds and large institutions have $6.34M invested in Bellerophon Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 18 closing their positions.
8.26% less ownership
Funds ownership: 22.04% → 13.78% (-8.3%)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
31% less funds holding
Funds holding: 39 → 27 (-12)
42% less capital invested
Capital invested by funds: $10.9M → $6.34M (-$4.52M)
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$134K |
| 2 |
Renaissance Technologies
New York
|
+$104K |
| 3 |
VF
Virtu Financial
New York
|
+$74K |
| 4 |
HF
HRT Financial
New York
|
+$61.9K |
| 5 |
E
Ergoteles
New York
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMVA
New Mountain Vantage Advisers
New York
|
-$1.31M |
| 2 |
BlackRock
New York
|
-$921K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
-$514K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$508K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$330K |
BLPH Hedge Fund Activity: Q2 2021 in Review
27 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2021, worth a combined $6.34M — down 42% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BLPH and 6 opened new positions — a net loss of 12 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Telemetry Investments, adding an estimated $134K. The largest seller was New Mountain Vantage Advisers, exiting entirely with an estimated $1.31M sold.
- 27 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2021, down from 39 in Q1 2021.
- Funds reported $6.34M of Bellerophon Therapeutics, Inc. stock for Q2 2021, down 42% quarter-over-quarter.
- 6 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2021 and 18 closed out, a net change of -12 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2021 was Telemetry Investments, an estimated $134K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2021 was New Mountain Vantage Advisers, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2021.